Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

Sponsors

Lead Sponsor: Nikkei (Canada) Marketing Limited

Source Nikkei (Canada) Marketing Limited
Brief Summary

The primary objective of this study is to determine the effects of Mikei® Red Reishi Essence EX extract powder on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.

Detailed Description

The purpose of this study is to determine the effects of Mikei® Red Reishi Essence EX, a natural supplementary dietary product, on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate. According to limited published scientific research and clinical studies, Reishi mushroom extract may support the body's immune function. According to cancer immunology research, at early stage of tumor development, the immune system can mount defensive actions to eliminate or inhibit tumor growth. This study is to examine the specific effect of Mikei® Red Reishi Essence EX on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.

Overall Status Withdrawn
Start Date 2020-11-05
Completion Date 2021-03-01
Primary Completion Date 2021-03-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Changes in the immune function of the prostate cancer patients and patients with non-cancerous prostate conditions by taking reishi extract product. The immune function will be analyzed using D2Dx test by measuring the relative IgG level in the blood. 6 months
Secondary Outcome
Measure Time Frame
Correlation between the immune function as expressed in the IgG level in the blood and the disease status (determined by PSA, DRE changes, and Gleason score) of prostate cancer patients. 6 months
Condition
Intervention

Intervention Type: Dietary Supplement

Intervention Name: Mikei Red Reishi Essence EX

Description: Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.

Arm Group Label: Mikei Red Reishi Essence EX

Intervention Type: Dietary Supplement

Intervention Name: Placebo

Description: Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.

Arm Group Label: Placebo

Eligibility

Criteria:

Inclusion Criteria: 1. Male age between 50-85 2. Diagnosed with prostate cancer or high-grade PIN within the last 24 months through the most recent biopsy; or patients who have a total PSA level above 4.0 but have not been diagnosed with prostate cancer yet 3. Has not received any prostate cancer therapy including surgery, chemotherapy, hormone therapy, or radiation therapy 4. Clinical Gleason score of the tumor is ≤6 for patients ≤70 years or ≤7 for >70 years; (non-applicable for non-cancer patients with elevated PSA or high-grade PIN) 5. The clinical stage of the cancer is T1c or below (non-applicable for non-cancer patients with elevated PSA or high-grade PIN) 6. The patients have been recommended for and placed under active surveillance without immediate treatment 7. Able to provide written informed consent Exclusion Criteria: 1. Patients taking mushroom (including reishi) or other herbal products/natural supplements 2. Patients with a known allergy to mushrooms 3. Prisoners 4. Patients who receive treatment with 5-alpha reductase inhibitors (finasteride [Propecia®, Proscar®,], or dutasteride [Avodart®) within 28 days prior to randomization are not eligible. The use of these drugs is not allowed during the patients' study participation. 5. Patients with a history of non-cutaneous malignancy in the previous 5 years are not eligible. 6. Patients taking warfarin, heparin, Aspirin >81mg/day, or other prescribed blood thinners: Reishi may increase the risk of bleeding. 7. Patients with platelets levels below 139 X 103/ul or history of bleeding disorders 8. Patients undergoing chemotherapy: Reishi may make some chemotherapy drugs less effective. 9. Patients with any known immune disorder, including but not limited to HIV or other primary or secondary immune deficiency diseases, autoimmune diseases, history of or being considered for organ transplants, etc. 10. Patients taking immunosuppressants (Corticosteroids, Calcineurin inhibitors, mTOR inhibitors, IMDH inhibitors, Biologics, Monoclonal antibodies): Reishi can stimulate immune responses. 11. Patients taking cytochrome P450 2E1, 1A2, and 3A sensitive substrate drugs: Reishi may increase the risk of side effects of these drugs. 12. Patient has total bilirubin >1.5 MG/DL, alanine aminotransferase (ALT) >51 U/L or aspartate aminotransferase (AST) >46 U/L.

Gender:

Male

Minimum Age:

50 Years

Maximum Age:

85 Years

Healthy Volunteers:

No

Overall Official
Location
Facility: Orlando Health Medical Group Urology
Location Countries

United States

Verification Date

2021-03-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Mikei Red Reishi Essence EX

Type: Experimental

Description: There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).

Label: Placebo

Type: Placebo Comparator

Description: Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Prevention

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News